Table 3:
Anti-tumor activity in patients in combination expansion cohorts and previously treated with PD-1/PD-L1 inhibitors (Part E)
| Population | ORRa n (%) | DCRb n (%) | Median PFSc Months [95% CI] |
|---|---|---|---|
| Melanoma (n=40) | 4 (10) | 14 (36) | 1.9 [1.8, 3.7] |
| SCCHN (n=21) | 2 (10) | 9 (43) | 3.7 [1.9, 5.5] |
| NSCLC (n=20) | 1 (5) | 8 (40) | 2.1 [1.8, 3.9] |
Abbreviations: CI, confidence interval; CR, complete response; DCR, disease control rate; ORR, overall response rate; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; PFS, progression-free survival; PR, partial response; SCCHN, squamous cell cancer of the head and neck.
a
Best response of CR or PR
b
Best response of CR, PR, or stable disease.
c
Based on Kaplan-Meier estimates for all treated patients.